NGR-TNF in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: * Diagnosis of advanced solid tumor not amenable to any clinical improvement by current standard treatments * Preferably tumors well known to be very angiogenic (e.g., renal, colon, thyroid, and head and neck cancers) * No clinical signs of CNS involvement PATIENT CHARACTERISTICS: Age * Over 18 Performance status * ECOG 0-2 OR * WHO 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 Hepatic * Bilirubin \< 1.5 times upper limit of normal (ULN) * AST and/or ALT \< 2.5 times ULN (5 times ULN in the presence of liver metastases) Renal * Creatinine \< 1.5 times ULN Cardiovascular * Cardiac function normal * No uncontrolled hypertension * No condition in which hypovolemia and its consequences (e.g., increased stroke volume, elevated blood pressure) or hemodilution could represent a risk to the patient Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * No active or uncontrolled systemic infection * No other uncontrolled disease, serious illness, or medical condition that would preclude study participation * No known hypersensitivity/allergic reaction to human albumin preparations or any of the excipients * No psychological, familial, sociological, or geographical condition that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy * At least 28 days since prior immunotherapy Chemotherapy * At least 28 days since prior chemotherapy and recovered Endocrine therapy * At least 28 days since prior hormonal therapy Radiotherapy * At least 28 days since prior radiotherapy and recovered * No prior radiotherapy to \> 25% of bone marrow reserve Surgery * More than 2 weeks since prior surgery Other * No other concurrent anticancer therapy * No other concurrent investigational agents